Table 3.

Teriflunomide treatment duration and reasons for stopping.

Characteristic	n	Value
Exposure, %
Duration of observation, days, mean (SD)	1072	495 (277)
Follow-up period, mean (days ± SD)
approximately 3 months (93.9 ± 26.8)	989	87.7
approximately 6 months (195.7 ± 49.5)	882	78.2
approximately 12 months (365.1 ± 65.7)	758	67.2
approximately 18 months (543.3 ± 67.4)	630	55.9
approximately 24 months (725.4 ± 76.9)	512	45.4
Main reason for discontinuation (total n = 242; multiple responses possible), %
Insufficient efficacy	55	22.7
Adverse events	97	40.1
Desire to have children	5	2.1
Pregnancy	1	0.4
Wish for treatment break	22	9.1
Assumed lack of compliance	22	9.1
Other	56	23.1

Values are means (±standard deviation) or percentages.

SD, standard deviation.